Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Robin

Showing results (201-210 of 298) with videos related to

Pageof 30
Sort By:
Blood Advances|July 15, 2024
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasmsYves Chalandon, Diderik-Jan Eikema, Ivan Moiseev, et al.
American Journal of Hematology|October 27, 2020
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide studyJean-Baptiste Bossard, Jean-Baptiste Beuscart, Marie Robin, et al.
Acta Haematologica|January 5, 2023
On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid LeukemiaCharles Guisnel, Luciane Schirmer, Stéphane Morisset, et al.
Leukemia|December 22, 2018
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemiaJohannes Schetelig, Liesbeth C de Wreede, Michel van Gelder, et al.
Leukemia|April 15, 2020
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantationJuan Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Blood|January 22, 2015
CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host diseaseAdèle de Masson, Jean-David Bouaziz, Hélène Le Buanec, et al.
The Canadian Journal of Cardiology|March 25, 2026
Risk of Post-Transplant Cyclophosphamide-Related Cardiotoxicity in Allogeneic Stem Cell TransplantationRayane Hadjali, Florian Chevillon, Benjamin Sibilia, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2012
Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2Anne Rullier, Sophie Gourgou-Bourgade, Marta Jarlier, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Transplantation and Cellular Therapy|November 27, 2022
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice GuidelinesZachariah DeFilipp, Stefan O Ciurea, Corey Cutler, et al.
Pageof 30

Showing results (201-210 of 298) with videos related to

Sort By:
Pageof 30
Blood Advances|July 15, 2024
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasmsYves Chalandon, Diderik-Jan Eikema, Ivan Moiseev, et al.
American Journal of Hematology|October 27, 2020
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide studyJean-Baptiste Bossard, Jean-Baptiste Beuscart, Marie Robin, et al.
Acta Haematologica|January 5, 2023
On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid LeukemiaCharles Guisnel, Luciane Schirmer, Stéphane Morisset, et al.
Leukemia|December 22, 2018
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemiaJohannes Schetelig, Liesbeth C de Wreede, Michel van Gelder, et al.
Leukemia|April 15, 2020
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantationJuan Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Blood|January 22, 2015
CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host diseaseAdèle de Masson, Jean-David Bouaziz, Hélène Le Buanec, et al.
The Canadian Journal of Cardiology|March 25, 2026
Risk of Post-Transplant Cyclophosphamide-Related Cardiotoxicity in Allogeneic Stem Cell TransplantationRayane Hadjali, Florian Chevillon, Benjamin Sibilia, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2012
Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2Anne Rullier, Sophie Gourgou-Bourgade, Marta Jarlier, et al.
British Journal of Haematology|March 2, 2019
Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemiaNicolaus Kröger, Diderik-Jan Eikema, Linda Köster, et al.
Transplantation and Cellular Therapy|November 27, 2022
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice GuidelinesZachariah DeFilipp, Stefan O Ciurea, Corey Cutler, et al.
Pageof 30